IntraDose: MATX said that in a Phase II open-label study of IntraDose to treat inoperable primary liver cancer, the product gave an overall response rate of 53%

Matrix Pharmaceutical Inc. (MATX), Fremont, Calif.
Product: IntraDose
Business: Cancer
Therapeutic category: Cytotoxic
Target:

Read the full 140 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE